| خلاصه مقاله | Aim/Introduction: In metastatic castration-resistant prostate cancer (mCRPC), radiopharmaceutical therapies using Lutetium-177 prostate-specific membrane antigen (PSMA) ligands are showing
promising results. Clinical trials have shown these radiopharmaceuticals to reduce
prostate-specific antigen (PSA) levels and improve progression-free survival. Patient-specific activity
personalization is currently impossible due to the lack of absorbed dose-effect relationships. This
.makes it difficult to accurately calculate the amount of radiation needed to treat each patient
Radiopharmaceutical therapies need dosimetry to be integrated into the standard workflow using
(simplified imaging protocols such as single time point (STP
rather than multi-time point (MTP). Our goal is to evaluate the differences between
image-based dosimetry using STP and MTP for tumor treatment with 177Lu-PSMA-617
Method: A total of 20 patients with mCRPC had 177Lu-SPECT imaging data (24 hours, 36 hours, and 72
hours post-drug administration) available on the first 177Lu-PSMA-617 treatment cycle. Dosimetry was
conducted using two different methods, the MTP method which incorporated images from all imaging time
points, and the STP method. The STP method was used to assess dosimetry at a single time point. Tumors
were delineated using the difference between Gaussian curves. Based on tumor density and coefficient of
variation, support vector machines were used to classfy tumors. A receiver operating characteristic curve
was generated to evaluate the model’s performance. The model was validated using an independent test set
Results: The mean absorbed dose per time-integrated activity for tumors was 0.72 ± 0.12 (MTP
method), 0.75 ± 0.12 (STP method 24h-image), 0.65 ± 0.13(STP method 36h-image) and 0.57 ± 0.12 (STP
method 72h-image) Gy/GBq. There were no significant differences in the values of absorbed dose
between various dosimetry methods Conclusion: Based on our results, we conclude that the STP
method is reliable for measuring the amount of absorbed dose in tumors. Since normal tissue
protection will be useful for improving cure rates and decreasing patient morbidity, STP can help to solve a key
challenge in radiopharmaceutical therapies which is to receive maximum doses to cancer cells while
minimizing damage to healthy tissue. This method can also be used to predict the efficacy of
radiopharmaceutical therapies in mCRPC patients controlling tumor growth and preventing numerous side
effects of multiple-course chemo-radiation therapies due to high doses of these methods. Additionally,
.the STP method can be used to monitor the success of radiopharmaceutical therapies in cancer patients |